SCHEMBL19541640

SCHEMBL19541640

COC(C)N1Cc2c(O)cccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 1/20 0.41
▸ ANPEP P15144 1/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ UGCG Q16739 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ PHGDH O43175 1/20 0.35
▸ IDH1 O75874 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ THRB P10828 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19222203 0.74 NPC1 (0.38) CRBNPARP1NPC1RAB9AMEN1
SCHEMBL20766676 0.73 NPC1 (0.48) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL20766677 0.73 NPC1 (0.48) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL27899038 0.73 ALOX15 (0.39) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL19370098 0.73 CRBN (0.48) CRBNANPEPDPP4PARP1UGCG
SCHEMBL2251395 0.72 NPC1 (0.40) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL29388571 0.72 NPC1 (0.40) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL2254579 0.72 NPC1 (0.47) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL2248688 0.72 NPC1 (0.40) CRBNNPC1RAB9AMEN1KMT2A
SCHEMBL29471925 0.72 NPC1 (0.40) CRBNNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017492-B2 Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (CN) 2018-07-10 — — US disclosed
US-20170313676-A1 ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF KANGPU BIOPHARMACEUTICALS, LTD. (CN) 2017-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017492-B2 Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof IL2, IL1B, IL5 CRBN 3765/4885ANPEP 3095/4885DPP4 1900/4885
US-20170313676-A1 ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF IL2, IL1B, IL5 CRBN 3765/4885ANPEP 3095/4885DPP4 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback